Quantum Healthcare Limited and its subsidiaries

CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	Group 6 months ended 30 June 2023 S$'000	30 June 2022 S$'000	Change
Revenue	6	6,296	4,119	52.8%
Cost of sales		(3,493)	(2,250)	55.2%
Gross profit		2,803	1,869	50.0%
Administrative expenses		(5,257)	(2,834)	85.5%
Research and development expenses		–	(23)	(100%)
Other income		115	94	22.5%
Results from operating activities		(2,339)	(894)	>100%
Finance costs		(251)	(106)	>100%
Net finance costs		(251)	(106)	>100%
Loss before taxation	7	(2,590)	(1,000)	>100%
Tax expense		(45)	(50)	(9.1%)
Loss for the period		(2,635)	(1,050)	>100%
Other comprehensive loss				
Item that is or may be reclassified subsequently to profit or loss:				
Foreign currency translation differences		(6)	279	(>100%)
Total comprehensive loss for the period		(2,641)	(771)	>100%
Loss attributable to:				
- Owners of the Company		(2,727)	(1,004)	>100%
- Non-controlling interests		92	(46)	(>100%)
Loss for the period		(2,635)	(1,050)	>100%
Total comprehensive loss attributable to:				
- Owners of the Company		(2,733)	(725)	>100%
- Non-controlling interests		92	(46)	(>100%)
Total comprehensive loss for the period		(2,641)	(771)	>100%
Loss per share for the loss attributable to the owners of the Company during the period:				
Basic (S$)	16	(0.0004)	(0.0002)	
Diluted (S$)	16	(0.0004)	(0.0002)	

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

	Note	Group		Company	
		30 June 2023 S$'000	31 December 2022 S$'000	30 June 2023 S$'000	31 December 2022 S$'000
Assets:					
Plant and equipment	9	780	827	–	–
Goodwill		5,679	4,120	–	–
Intangible assets	10	573	688	–	–
Investment in subsidiaries	11	–	–	7,573	7,573
Right-of-use assets		1,780	2,295	–	–
Other non-current assets		76	45	–	–
Non-current assets		8,888	7,975	7,573	7,573
Inventories		77	32	–	–
Trade and other receivables		2,308	1,707	84	7
Cash and cash equivalents		2,459	5,195	560	1,062
Current assets		4,844	6,934	644	1,069
Total assets		13,732	14,909	8,217	8,642
Equity:					
Share capital	14	236,230	234,230	236,230	234,230
Reserves		8,687	8,690	(228,714)	(228,714)
Accumulated losses		(247,570)	(244,840)	(7,643)	(6,861)
Equity attributable to owners of the Company		(2,653)	(1,920)	(127)	(1,345)
Non-controlling interests		384	292	–	–
Total equity		(2,269)	(1,628)	(127)	(1,345)
Liabilities:					
Deferred tax liabilities		62	61	–	–
Lease liabilities		855	1,294	–	–
Loans and borrowings	12	3,605	4,238	–	–
Amount due to a non-controlling interest		1,247	2,563	1,247	2,563
Non-current liabilities		5,769	8,156	1,247	2,563
Lease liabilities		953	1,001	–	–
Loans and borrowings	12	1,341	1,309	–	–
Amount due to a non-controlling interest		1,383	1,383	1,383	1,383
Trade and other payables	13	6,329	4,477	5,714	6,041
Provision for reinstatement costs		155	155	–	–
Provision for income tax		71	56	–	–
Current liabilities		10,232	8,381	7,097	7,424
Total liabilities		16,001	16,537	8,344	9,987
Total equity and liabilities		13,732	14,909	8,217	8,642

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

	Attributable to owners of the Company								
	Ordinary shares S$'000	Other reserve S$'000	Reserve for own shares S$'000	Translation reserve S$'000	Share-based payment reserve S$'000	Accumulated (losses)/profits S$'000	Attributable to equity holders of the Company S$'000	Non-controlling interests S$'000	Total equity S$'000
Group									
At 1 January 2023	234,230	(1,866)	(98)	(1,024)	11,678	(244,840)	(1,920)	292	(1,628)
Total comprehensive loss for the period									
Loss for the period	–	–	–	–	–	(2,727)	(2,727)	92	(2,635)
Other comprehensive loss									
Foreign currency translation differences	–	–	–	(3)	–	(3)	(6)	–	(6)
Total comprehensive loss for the period	–	–	–	(3)	–	(2,730)	(2,733)	92	(2,641)
Contribution by and distribution to owners									
Share issued pursuant to share placement	2,000	–	–	–	–	–	2,000	–	2,000
Total contribution by and distribution to owners	2,000	–	–	–	–	–	2,000	–	2,000
At 30 June 2023	236,230	(1,866)	(98)	(1,027)	11,678	(247,570)	(2,653)	384	(2,269)

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

	Attributable to owners of the Company								
	Ordinary shares S$'000	Other reserve S$'000	Reserve for own shares S$'000	Translation reserve S$'000	Share-based payment reserve S$'000	Accumulated (losses)/profits S$'000	Attributable to equity holders of the Company S$'000	Non-controlling interests S$'000	Total equity S$'000
Group									
At 1 January 2022	235,187	(1,866)	(104)	(4,830)	11,592	(242,374)	(2,395)	(197)	(2,592)
Total comprehensive loss for the period									
Loss for the period	–	–	–	–	–	(1,004)	(1,004)	(46)	(1,050)
Other comprehensive loss									
Effects of changes in functional currency	(9,647)	2,363	5	(416)	86	6,229	(1,380)	–	(1,380)
Foreign currency translation differences	–	–	–	1,659	–	–	1,659	–	1,659
Total comprehensive loss for the period	(9,647)	2,363	5	1,243	86	5,225	(725)	(46)	(771)
Contribution by and distribution to owners									
Share issued pursuant to share placement	7,300	–	–	–	–	–	7,300	–	7,300
Shares issued pursuant to business combination	500	–	–	–	–	–	500	–	500
Total contribution by and distribution to owners	7,800	–	–	–	–	–	7,800	–	7,800
Change in ownership interests									
Acquisition of partial interest in a subsidiary	–	–	–	–	–	–	–	61	61
Total change in ownership interest	–	–	–	–	–	–	–	61	61
Total transaction with owners of the Company	7,800	–	–	–	–	–	7,800	61	7,861
At 30 June 2022	233,340	497	(99)	(3,587)	11,678	(237,149)	4,680	(182)	4,498

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

	Attributable to owners of the Company							
Company	**Ordinary shares S$'000**	**Capital reserve S$'000**	**Reserve for own shares S$'000**	**Capital contribution S$'000**	**Translation reserve S$'000**	**Share-based payment reserve S$'000**	**Accumulated losses S$'000**	**Total equity S$'000**
At Date of Incorporation / 30 May 2022	–	–	–	–	–	–	–	–
Contribution by and distribution to owners								
Issue of ordinary shares	#	–	–	–	–	–	–	#
Total contribution by and distribution to owners	#	–	–	–	–	–	–	#
At 30 June 2022	#	–	–	–	–	–	–	#
At 1 January 2023	234,230	(228,762)	–	–	–	48	(6,861)	(1,345)
Other comprehensive loss								
Loss for the period	–	–	–	–	–	–	(782)	(782)
Total comprehensive loss for the period	–	–	–	–	–	–	(782)	(782)
Contribution by and distribution to owners								
Share issued pursuant to share placement	2,000	–	–	–	–	–	–	2,000
Total contribution by and distribution to owners	2,000	–	–	–	–	–	–	2,000
At 30 June 2023	236,230	(228,762)	–	–	–	48	(7,643)	(127)

denote below S$1,000

CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

	Group	
	6 months ended	
	30 June 2023	30 June 2022
	S$'000	S$'000
Cash flows from operating activities		
Loss before income tax	(2,590)	(1,000)
Adjustments for:		
- Depreciation of plant and equipment	88	23
- Depreciation of right-of-use assets	472	446
- Amortisation of intangible assets	115	–
- Effects of changes in functional currency	–	369
- Interest expenses	251	27
	(1,664)	(135)
Change in:		
- Trade and other receivables	(608)	(1,040)
- Trade and other payables	1,852	(332)
- Inventories	(45)	–
- Other assets	(29)	1
Cash used in operations	(494)	(1,506)
Interest expenses paid	–	(27)
Income taxes paid	(30)	(8)
Total net cash used in operating activities	(524)	(1,541)
Cash flows from investing activities		
Acquisition of subsidiary and business, net of cash acquired	(1,560)	(4,092)
Purchase of plant and equipment	(41)	(446)
Total net cash used in investing activities	(1,601)	(4,538)
Cash flows from financing activities		
Proceeds from issue of ordinary shares	2,000	7,300
Proceeds from borrowings	–	2,600
Repayment of borrowings	(731)	(498)
Repayment of lease liabilities	(496)	(380)
Repayment of amount due to non-controlling interest	(1,383)	–
Total net cash used in/from financing activities	(610)	9,022
Net increase/(decrease) in cash and cash equivalents	(2,735)	2,943
Effect of exchange rate changes on cash and cash equivalents	(1)	5
Cash and cash equivalents at beginning of period	5,195	344
Cash and cash equivalents at end of year	2,459	3,292

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

These notes form an integral part of and should be read in conjunction with the consolidated financial statements.

1 General Information

Quantum Healthcare Limited (the "**Company**") is a public limited liability company incorporated and domiciled in Singapore and whose shares are publicly traded on the Catalist board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"). These condensed interim consolidated financial statements as at and for the six months ended 30 June 2023 comprise the Company and its subsidiaries (collectively, the "**Group**").

The principal activity of the Company is that of investment holding. The principal activities of the subsidiaries are:

<u>(i) Vascular Business</u>
(a) development, manufacturing and distribution of medical devices; and
(b) support services to related corporations for the development, manufacturing and distribution of medical devices.

<u>(ii) Healthcare Business</u>
(a) provision of dental services;
(b) management consultancy services for healthcare organisations and dental services; and
(c) research, develop and design of medical related products.

2 Basis of Preparation

The condensed interim financial statements for the six months ended 30 June 2023 have been prepared in accordance with Singapore Financial Reporting Standard (International) ("**SFRS(I)**") 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.2.

The condensed interim financial statements are presented in Singapore Dollars which is the Company's functional currency.

2.1 Going concern assumption

For the financial period ended 30 June 2023, the Group incurred a net loss and a total comprehensive loss of S$2,635,000 (30 June 2022: S$1,050,000) and S$2,641,000 (30 June 2022: S$771,000), respectively, and has net cash used in operating activities of S$524,000 (30 June 2022: S$1,541,000). As at 30 June 2023, the Group has a net current liabilities and deficit shareholders' equity of S$5,388,000 (31 December 2022: S$1,447,000) and S$2,269,000 (31 December 2022: S$1,628,000), respectively, and the Company has a net current liabilities and deficit shareholders' equity of S$6,453,000 (31 December 2022: S$6,355,000) and S$127,000 (31 December 2022: S$1,345,000), respectively.

2.1 Going concern assumption (cont'd)

The above conditions indicate the existence of a material uncertainty that may cast significant doubt on the ability of the Group and the Company to continue as going concerns and therefore they may be unable to realize their assets and discharge their liabilities in the normal course of business.

Notwithstanding the above, the directors of the Company believe that the use of the going concern assumption in the preparation and presentation of the condensed interim consolidated financial statements for the financial period ended 30 June 2023 is appropriate after taking into account the following considerations:

i. Management is of the view that the Group will have sufficient working capital for at least the next 12 months from the date of these condensed interim consolidated financial statements and will be able to meet its obligations as and when they fall due within such period based on the Group's cash flow forecast for the next 12 months, which has been prepared, *inter alia*, on the premises as further elaborated below.

In the preparation of the Group's cash flow forecast, no provision has been made for (a) payment of the final milestone payment of EUR 500,000 ("**Final Milestone Payment**") together with accrued interest thereon and the arbitration related costs of US$119,875 ("**Arbitration Related Costs**") which, under the terms of the final award ("**Award**") in respect of the arbitration proceedings for the InnoRa Dispute ("**Arbitration**"), are due and payable by TriReme Singapore (S) Pte Ltd ("**TriReme Singapore**") and Quattro Vascular Pte Ltd ("**Quattro**") (collectively the "**Claimants**", and QTV, TriReme USA, TriReme Singapore and Quattro are collectively referred to as the "**QTV Group**") to InnoRa GMBH ("**InnoRa**") and (b) payment of the outstanding legal fees of approximately S$ 2.7 million payable to the Claimants' legal counsels in connection with the Arbitration ("**Arbitration Legal Expenses**"), inter alia, for the following reasons:

a. Under the Sub-Licence Agreement dated 28 August 2020 previously entered into between QT Vascular Limited ("**QTV**"), TriReme Medical LLC ("**TriReme USA**"), G Vascular Private Limited ("**G Vascular**") and Genesis Medtech International Private Limited ("**Genesis Medtech**", and together with G Vascular, the "**Genesis Group**"), G Vascular had agreed to make a one-time milestone payment of EUR 500,000 directly to InnoRa within 60 days after the receipt of the FDA approval for Chocolate Touch® ("**Product**") sold to G Vascular under the asset purchase agreement entered into between QTV, TriReme USA and the Genesis Group on 27 August 2020 ("**APA**"), which FDA approval was obtained on 4 November 2022. The Group will be following up with G Vascular for it to comply with its obligation to pay InnoRa as aforesaid, and thereby satisfy the Claimants' obligation in respect of payment of the Final Milestone Payment.

2.1 Going concern assumption (cont'd)

b. The Genesis Group had previously paid for or funded part of the legal fees incurred by Claimants in connection with the Arbitration and under a letter agreement entered into in or around October 2022 between the QTV Group and the Genesis Group, it was agreed that such legal fees and other costs and expenses advanced by the Genesis Group at its discretion in connection with the Arbitration would be regarded as loans extended by the Genesis Group ("**Arbitration Loans**") and shall be repaid to the Genesis Group, inter alia, from any amounts which may be owing from the Genesis Group to any members of the QTV Group under the APA including any Specified Proceeds Payments or Sales Payments (both as defined under the APA).

   It was also agreed that the Arbitration Loans would bear interest at the rate of 6% per annum as from 30 June 2023, and the Genesis Group shall not otherwise have any recourse against Claimants or the Company for repayment of the Arbitration Loans and/or accrued interest.

   Please refer to paragraph 18 of this announcement and the Company's announcement dated 29 July 2023 for further details of the Arbitration and the Award.

ii. Management will continue to implement comprehensive cost-containment measures and does not expect the Group to have any significant operational commitments that will require significant cash outflow in the next 12 months other than those incurred in the ordinary course of business;

iii. Following the receipt of the Company shareholders' approval at an extraordinary general meeting held on 27 March 2023 for a proposed share placement, the share placement has been completed on 28 March 2023 and the Company received a gross share placement proceeds of S$2.0 million which will be used for general working capital purposes of the Group;

iv. The Group has diversified into the healthcare business, primarily the provision of dental services, which are profitable and generating positive cash flows for the Group. The Group's acquisition of 100% of the businesses of three (3) clinics, via ADG's subsidiary, The Dental Hub Pte. Ltd during the financial period (please refer to Note 17 below for more details) has contributed positively to the Group's performance for the financial period and is expected to remain profitable for the next 12 months; and

v. Management continues to explore the possibility of corporate actions involving entering into new business opportunities to generate new sources of revenue and/or fund-raising exercises.

The above considerations are premised on future events which are inherently uncertain. In the event that the Group and the Company are unable to continue as going concerns, the Group and the Company may be unable to discharge their liabilities in the normal course of business and adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are recorded in the statement of financial position. In addition, the Group and the Company may have to provide for further liabilities that might arise, and to reclassify non-current assets and non-current liabilities as current assets and current liabilities respectively. No such adjustments have been made to these interim condensed consolidated financial statements as at 30 June 2023.

2.2 New and amended standards adopted by the Group

The Group has adopted all the applicable new and SFRS(I) and Interpretations of SFRS(I) ("**INT SFRS(I)**") that are relevant to its operations and effective for annual periods beginning on 1 January 2023. The adoption of these new and revised SFRS(I) and INT SFRS(I) did not result in any substantial change to the Group's accounting policies or result in retrospective adjustments as a result of adopting those standards.

2.3 Use of judgement and estimates

In preparing the condensed interim consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited consolidated financial statements for FY2022.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.
Management is of the opinion that there were no significant judgements made in applying the accounting policies in the condensed interim financial statements.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following notes:

<u>Expected credit losses ("ECL") on trade receivables</u>

ECL are unbiased probability-weighted estimates of credit losses which are determined by evaluating a range of possible outcomes and taking into account past events, current conditions and assessment of future economic conditions.

The Group has used relevant historical information and loss experience to determine the probability of default of the instruments and incorporated forward-looking information, including significant changes in external market indicators which involved significant estimates and judgements.

In determining the ECL, management has taken into account the historical default experience and the financial position of the counterparties, adjusted for factors that are specific to these receivables in estimating the probability of default of each of other receivables.

Notwithstanding the above, the Group evaluates the expected credit loss on customers in financial difficulties separately. No loss allowances on trade receivables are recognised by the Group for the financial period ended 30 June 2023.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Operating segments

Operating segments are defined as components of an enterprise that engage in business activities for which separate financial information is available and evaluated by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company's chief operating decision maker is its CEO. The CEO reviews financial information presented on a consolidated basis, for purposes of allocating resources and evaluating financial performance. The Group has one business activity and there are no segment managers who are held accountable for operations, or plans for levels or components below the consolidated unit level. Accordingly, the Group operate as a single reportable operating segment. The Group's reportable segments are (i) Vascular Business, (ii) Healthcare Business and (iii) Corporate. Please refer to Note 1 for principal business of subsidiaries.

Corporate segment consists of investment holding company which does not meet any of the quantitative threshold for determining a reportable operating segment criteria for the six months ended 30 June 2022 and 30 June 2023.

Information regarding results of each reportable segment is included below. Performance is measured based on segment profit (loss) before tax, as included in the internal management reports reviewed by the Company's CEO. Segment profit (loss) is used to measure performance as management believes that such information is the most relevant in evaluation the results of certain segments relative to other entities that operate within these industries.

4. **Operating segments** (cont'd)

Information about reportable segments

	Reportable Segments							
	Vascular Business		**Healthcare Business**		**Corporate**		**Total**	
	30 June 2023 S$'000	**30 June 2022 S$'000**	**30 June 2023 S$'000**	**30 June 2022 S$'000**	**30 June 2023 S$'000**	**30 June 2022 S$'000**	**30 June 2023 S$'000**	**30 June 2022 S$'000**
Group								
External revenues	–	–	6,296	4,119	–	–	6,296	4,119
Segment profit/(loss) before tax[1]	(2,172)	(332)	487	292	(905)	(960)	(2,590)	(1,000)
Segment assets*	433	660	6,403	4,817	644	2,374	7,480	7,851
Segment liabilities	(6,143)	(1,019)	(6,939)	(4,348)	(2,919)	(6,801)	(16,001)	(12,168)

Note: 1) For six month ended 30 June 2023 ("**HY2023**"), excluding non-operating Arbitration Legal Expenses of S$2.0 million attributed to InnoRa Dispute, the total loss before tax would have been S$590,000, an improvement of S$410,000 from six month ended 30 June 2022 ("**HY2022**"). This improvement is mainly attributed to the growth in healthcare segment which is the core operating business for the Group.

Geographical segments

The Group operates principally in the United States of America and Singapore. In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers and segment assets are based on the geographical location of the non-current assets.

	Revenue		**Non-current assets***	
	30 June 2023 S$'000	**30 June 2022 S$'000**	**30 June 2023 S$'000**	**30 June 2022 S$'000**
Group				
United States of America	–	–	197	438
Singapore	6,296	4,119	2,439	2,722
	6,296	4,119	2,636	3,160

*Segment assets and non-current assets excludes goodwill and intangibles asset.

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group and Company as at 30 June 2023 and 31 December 2022:

	Group		Company	
	30 June 2023 S$'000	**31 December 2022 S$'000**	**30 June 2023 S$'000**	**31 December 2022 S$'000**
Financial Assets				
Other non-current assets	76	45	–	–
Trade and other receivables	2,179	1,645	–	–
Cash and bank balances	2,459	5,195	560	1,062
	4,714	6,885	560	1,062
Financial Liabilities				
Trade and other payables	(6,329)	(4,477)	(266)	(439)
Loans and borrowings	(4,946)	(5,547)	–	–
Lease liabilities	(1,808)	(2,295)	–	–
Amount due to non-controlling interest	(2,630)	(3,946)	(2,630)	(3,946)
	(15,713)	(16,265)	(2,896)	(4,385)
Net financial (liabilities)	(10,999)	(9,380)	(2,336)	(3,323)

6. Revenue from Contracts with Customers

Disaggregation of revenue from contract with customers

The Group's revenue is disaggregated by major product lines and timing of revenue recognition. This is consistent with the segment revenue information as disclosed in Note 4.

	Group 6 months ended	
	30 June 2023 S$'000	**30 June 2022 S$'000**
Type of good or services		
Sale of services	6,296	4,119
Timing of transfer of good or services		
At a point in time	6,296	4,119

7. Loss before taxation

The followings items have been included in arriving at loss before taxation:

	Group 6 months ended	
	30 June 2023 S$'000	**30 June 2022 S$'000**
Expenses		
Depreciation of plant and equipment	(88)	(23)
Depreciation of right-of-use assets	(472)	(446)
Exchange (loss)	#	–
Interest expense	(251)	(27)

denote below S$1,000

8. Net (Liability) Value

	Group		Company	
	30 June 2023	31 December 2022	30 June 2023	30 December 2022
	S$	S$	S$	S$
Net (liability) value per ordinary share (1), (2)	(0.00030)	(0.00024)	(0.00002)	(0.00020)

Notes:

(1) The net liability value per ordinary share of the Group is calculated based on net liabilities of S$2,269,000 as at 30 June 2023 (31 December 2022: net liabilities of S$1,628,000). The net liability value per ordinary share of the Company is calculated based on net liabilities of S$127,000 as at 30 June 2023 (31 December 2022: net liabilities of S$1,345,000).

(2) The net liability value per ordinary share for Group and Company were calculated based on 7,464,501,108 ordinary shares in issue as at 30 June 2023 and 6,893,072,508 ordinary shares in issue as at 31 December 2022.

9. Plant and equipment

During the six month ended 30 June 2023, the Group acquired assets amounting to S$41,000 (30 June 2022: S$446,000). There is no disposal during the six month ended 30 June 2023 (30 June 2022: S$Nil).

10. Intangible assets

Group	Intellectual property S$'000	Developed technology in progress S$'000	Customer relationship* S$'000	Total S$'000
Cost				
At 1 January 2022 / 2023	501	1,922	–	2,423
Additions due to acquisition	–	–	917	917
As at 30 June 2023 / 31 December 2022	501	1,922	917	3,340
Accumulated amortisation and impairment loss				
At 1 January 2022	501	1,922	–	2,423
Amortisation for the year	–	–	229	229
At 31 December 2022	501	1,922	229	2,652
Amortisation for the period	–	–	115	115
At 30 June 2023	501	1,922	344	2,767
Net book value				
At 31 December 2022	–	–	688	688
At 30 June 2023	–	–	573	573

* Arose from the acquisition of ADG Group

11. Investment in Subsidiaries

	Company	
	30 June 2023 S$'000	31 December 2022 S$'000
Unquoted equity shares, at cost		
- QT Vascular Ltd	5,516	5,516
- Asia Dental Group Pte. Ltd.	8,129	8,129
- Kairogenix Pte. Ltd.	#	#
- Quantum Healthcare Holdings Sdn. Bhd.	#	–
	13,645	13,645
Less: Allowance for impairment loss		
At 1 January	(6,072)	–
Additions	–	(6,072)
At 30 June 2023 / 31 December 2022	(6,072)	(6,072)
	7,573	7,573

denote below S$1,000

Interest in a subsidiary with material non-controlling interests

The Group has the following subsidiary that has material non-controlling interests:

Name of subsidiary	Place of incorporation and principal place of business	Effective equity interest held by Group	
		30 June 2023	31 December 2022
TriReme Medical LLC ("**TriReme USA**")*	United States of America	50% + 1 Share	50% + 1 Share
Asia Dental Group Pte. Ltd. ("**ADG**")	Singapore	60%	60%
Kairogenix Pte Ltd ("**Kairogenix**")	Singapore	70%	70%
Quantum Healthcare Holdings Sdn. Bhd. ("**QHHSB**")	Malaysia	60%	–

Note: * As per announcement dated 17 February 2023, the management of the Company have been made aware of purported capital call carried out by TriReme USA management, which resulted in dilution of the Company's shareholdings in TriReme USA. The Management of the Company is still seeking clarifications from TriReme USA on this matter, pending mutual resolution, has expressly reserved its rights to dispute such purported corporate action of TriReme USA. Accordingly, the Company continues to consolidate TriReme USA as a subsidiary of the Group in the interim consolidated financial statements as at and for the six months ended 30 June 2023.

11. Investment in Subsidiaries (cont'd)

Interest in a subsidiary with material non-controlling interests (cont'd)

	Profit / (Loss) allocated to non-controlling interests 30 June 2023 S$'000	Accumulated non-controlling interests 30 June 2023 S$'000
TriReme USA	(83)	(388)
ADG	177	784
Kairogenix	(1)	(11)
QHHSB	(1)	(1)
	92	(384)

12. Loans and borrowings

	Secured	
	30 June 2023 S$'000	31 December 2022 S$'000
Group		
Amount repayable within one year or less or on demand	1,341	1,309
Amount repayable after one year	3,605	4,238
	4,946	5,547

Details of loans and borrowings

<u>Loan from a related party</u>
The loan from a related party is secured by way of a share charge over the 60% shareholding in ADG. These 60% shares of ADG was transferred from QTV to the Company on 8 September 2022, and bears a fixed interest rate of 5.5% per annum. The disbursed loan amount was S$2 million and is repayable in 42 monthly instalments commencing in April 2022. As at 30 June 2023, the loan outstanding was S$1.5 million.

<u>Bank loans</u>
Other than the above loan, the subsidiaries also entered into several loans arrangements with banks for total loan amount of S$4.0 million which bears interest rate ranging between 4.75% - 6.5% p.a. and repayable over 48 - 60 months with starting range from 1 July 2022 to 1 December 2022. These bank loans are secured through corporate guarantee by the Company for 60% of the loan amount and personal guarantee by Dr Jimmy Gian, the Chief Operating Officer (Dental) of the Company for 40% of the loan amount, in proportion to their respective shareholdings in ADG.

13. Trade and other payables

	Group		Company	
	30 June 2023 US$'000	31 December 2022 US$'000	30 June 2023 US$'000	31 December 2022 US$'000
Trade payables	1,496	1,587	107	167
Accrued payroll and other related costs	69	70	36	–
Accrued operating expenses	4,366	1,757	123	272
Other payables	381	1,063	–	–
Amount due to subsidiary	–	–	5,448	5,602
Amount due to related parties	17	–	–	–
	6,329	4,477	5,714	6,041

14. Share capital

	Group			
	30 June 2023		31 December 2022	
	Number of ordinary shares '000	S$'000	Number of ordinary shares '000	S$'000
Issued and fully paid:				
At 1 January	6,893,073	234,230	2,559,739	235,188
Effect of change in functional currency	–	–	–	(9,647)
Share issued pursuant to share placement	571,428	2,000	4,055,556	7,300
Shares issued pursuant to business combination	–	–	277,778	1,389
At 30 June 2023 / 31 December 2022	7,464,501	236,230	6,893,073	234,230

	Company			
	30 June 2023		31 December 2022	
	Number of ordinary shares '000	S$'000	Number of ordinary shares '000	S$'000
Issued and fully paid:				
At 1 January / date of incorporation*	6,893,073	234,230	^	#
Shares issued pursuant to corporate restructuring	–	–	6,893,073	234,230
Share issued pursuant to share placement	571,428	2,000	–	–
At 30 June 2023 / 31 December 2022	7,464,501	236,230	6,893,073	234,230

The Group and Company does not hold any treasury shares and subsidiary holdings as at 30 June 2023 and 30 June 2022. As at 30 June 2023, the issued and paid-up share capital excluding treasury shares of the Company comprised 7,464,501,108 ordinary shares (30 June 2022: 1 ordinary share).

* The Company was incorporated on 30 May 2022.
^ The number of share issued at the date of incorporation was 1.
# Less than S$1,000.

15. Share-based Payment Arrangements

The Group has the following share-based payment arrangements:

Share option programme (equity-settled)

In September 2005 ("2005 Stock Plan"), November 2010 ("2010 Stock Plan") and September 2013 ("2013 Stock Plan"), QTV had established share option plans that entitle certain employees, directors and consultants to purchase ordinary shares in QTV. Further, in April 2014, QTV adopted the 2014 QTV Employee Share Option Scheme ("2014 Stock Plan") which had become effective upon the listing of QTV on the Catalist of the SGX-ST in April 2014.

As part of the corporate restructuring, all liabilities and obligations in connection with the outstanding share options ("Options") granted under QTV's 2005, 2010, 2013 and 2014 Stock Plans (collectively, the "Option Schemes") are assumed by the Company ("Options Variation"). The Options Variation do not involve any changes made to the terms of the share options granted or the rules of the Option Schemes except the outstanding Options will be exercisable into shares of the Company.

At 30 June 2023, the Option Schemes have 21 Optionholders with 12,186,536 outstanding Options. Details of the outstanding Options are set out below.

Options	Exercise price per share (S$)	Options outstanding at 30 June 2023	Number of Optionholders	Option period
2013 Stock Option	0.006	7,967,536	10	Ten years from date of grant
2014 Stock Option	0.095	4,219,000	11	Ten years from date of grant

The Company does not intend to issue additional Options under the Option Schemes.

Restricted share awards (equity-settled)

The QT Vascular Restricted Share Plan 2015 ("Award Scheme") was adopted to allow QTV to grant share awards ("Awards") to employees and directors of the Company or its subsidiaries, including controlling shareholders and their associates.

As part of the corporate restructuring, all liabilities and obligations in connection with the outstanding Awards granted under the Award Scheme are assumed by the Company ("Awards Variation"). The Awards Variation do not involve any changes made to the terms of the Awards granted or the rules of the Award Scheme except the outstanding Awards shall be reference to shares of the Company.

At 30 June 2023, the Award Scheme has 6 share awards holders with an aggregate of 1,241,544 outstanding Awards. The Company does not intend to grant additional Awards under the Award Scheme.

15. Share-based Payment Arrangements (cont'd)

Maximum number of Shares that may be issued on conversion of all Outstanding Convertibles ("**Maximum Issuable Shares**")

	As at 30 June 2023	**As at 30 June 2022**
(A) Options		
Number of unexercised Options	12,186,536	12,715,160
Maximum number of shares that may be issued on exercise of all unexercised Options ("**Maximum Issuable Option Shares**")	12,186,536	12,715,160
Maximum Issuable Option Shares as a % of Company's issued share capital as at the end of the respective financial periods	0.16%	0.18%
(B) Share Awards		
Number of Share Awards granted but not yet vested ("**Unvested Share Awards**")	1,241,544	1,241,544
Total number of shares which are the subject of Unvested Share Awards ("**Maximum Issuable Awards Shares**")	1,241,544	1,241,544
Maximum Issuable Awards Shares as a % of Company's issued share capital as at the end of the respective financial periods	0.02%	0.02%
Maximum number of Shares that may be issued on conversion of all Outstanding Convertibles ("Maximum Issuable Shares")	**13,428,080**	**13,956,704**
Maximum Issuable Shares as a % of Company's issued share capital as at the end of the respective financial periods	**0.18%**	**0.20%**

16. Loss per share

Group	6 months ended 30 June 2023	6 months ended 30 June 2022
Loss for the period/year attributable to owners of the Company **(S$'000)** used to compute:		
- Basic loss per share	(2,727)	(1,004)
- Diluted loss per share	(2,727)	(1,004)
Weighted average number of ordinary shares **('000)** used to compute:		
- Basic loss per share	7,166,089	6,605,780
- Diluted loss per share	7,166,089[1]	6,605,780[1]
Loss per share **(S$)**		
(a) Based on the weighted average number of ordinary shares	(0.0004)	(0.0002)
(b) On a fully diluted basis	(0.0004)	(0.0002)

Note:

(1) For the six months ended 30 June 2023 and 30 June 2022, the basic and diluted loss per share were the same as the outstanding options and warrants are anti-dilutive as the effect of the share conversions for any outstanding options and warrants would be to decrease the loss per share.

17. Acquisition of subsidiaries

(I) *Acquisition of dental clinics under the Dental Hub Group ("**TDH**")*

On 2 February 2023, ADG, a 60% owned subsidiary of the Group completed the acquisition of 100% of the businesses of three (3) clinics, via ADG's subsidiary, The Dental Hub Pte. Ltd., for a cash consideration of S$1,650,000. TDH is principally engaged in the provision of dental healthcare related services. TDH is not publicly listed.

The investment in TDH will enable the Group to grow its Healthcare business and is expected to contribute to the Group's overall revenue and profitability.

Since the completion of acquisition on 2 February 2023 and up to 30 June 2023, TDH contributed revenue of approximately S$1 million and profit of approximately S$156,000 to the Group's results. If the acquisition had occurred on 1 January 2023, management estimates that the consolidated revenue would have been S$1.2 million, and consolidated profit for the period would have been S$187,000. In determining these amounts, management has assumed that the fair value adjustments, determined provisionally, that arose on the date of acquisition would have been the same if the acquisition had occurred on 1 January 2023.

(A) Acquisition-related costs

The Group incurred acquisition-related costs of approximately S$85,000 relating to professional fees. These costs have been included in 'administrative expenses' in the condensed consolidated statement of profit or loss and other comprehensive income.

(B) Goodwill

As it was an acquisition of business, the consideration of S$1,650,000 was wholly allocated as goodwill arising on the acquisition of businesses of three clinics via TDH on consolidation.

18. Legal proceedings

In August 2021, InnoRa , a licensor to TriReme USA, a subsidiary of the Group, was seeking to claim for an amount of (i) US$1,200,000 in royalties, being 30% of the initial payment made to TriReme USA and QTV (collectively, the "**Sellers**"), under the APA between the Sellers and G Vascular ("**Purchaser**") and Genesis MedTech in relation to the disposal of the Product limited to specified applications involving the peripheral vascular system by Sellers to the Purchaser as announced in 27 August 2020, as well as (ii) 30% of all future payments received by Sellers in connection with the aforesaid disposal ("**InnoRa Dispute**").

In October 2021, Claimants, subsidiaries of the Group, filed for a demand for arbitration against InnoRa with the American Arbitration Association seeking declaratory judgements and certain damages from InnoRa. InnoRa had responded via counterclaims to claims made by Claimants in November 2021. Subsequently, in March 2022, Claimants responded to the statement of counterclaims made by InnoRa.

On 26 August 2022, InnoRa had filed a complaint with a state court in California involving allegations similar to those made in the InnoRa Dispute ("**Complaint**"). The Complaint made by InnoRa now includes QTV, TriReme USA, and the Genesis Group as parties to the Complaint (collectively, the "**Respondent**").

On 13 January 2023, a case management conference was held by the State Court to discuss the status of the Complaint. Considering that Claimants has an arbitration hearing for the InnoRa Dispute scheduled in March 2023, of which the outcome of the arbitration will have the same effect for this Complaint, the State Court agreed for the case management conference to be deferred to 16 May 2023.

On 26 July 2023, Claimants have received the Award of the arbitration proceedings for the InnoRa Dispute. The key terms of the Award are summarized below:

- The Arbitrator appointed by American Arbitration Association International Centre for Dispute Resolution ("**Arbitrator**") denied all claims made by either party, except for the payment of the Final Milestone Payment of EUR500,000 originally contracted to be paid by Claimants, which was due within 6 weeks of receipt of FDA approval for the Product. The Arbitrator also requires Claimants to accrue for a simple interest of 10% per annum from due date of 16 December 2022 until the date the payment is made.
- The Arbitrator also ruled that InnoRa does not have any valid claims for royalties for any sales of the Product in the United States by Claimants or the Purchaser.
- Further, Claimants were not required to assign the Development and Licensing Agreement to Purchaser in conjunction with the entry of the APA.
- As InnoRa is the only party which obtained monetary relief for final milestone payment, Arbitrator ordered Claimants to reimburse InnoRa with the sum of US$119,875, covering the administrative fees paid to AAA, within 30 days of the receipt of the Award.
- Other than the reimbursement and final milestone payment, each party shall bear their respective legal fees and any other relevant costs incurred during the Arbitration.

For more information on the Award, please refer to the SGX announcement dated 29 July 2023.

With respect to the Complaint, the State Court granted QTV's motion to compel arbitration on 24 April 2023. However, no demand for arbitration has been filed by InnoRa to date. Based on the Group's US legal counsel's advice, the Board of Directors of the Company are of the opinion that should InnoRa proceed with any demand for arbitration, the Respondents may object to the demand for arbitration on the ground that the arbitration is an attempt by InnoRa to reopen the InnoRa Dispute, despite the finality of the Award for the InnoRa Dispute. A further case management conference is set for 25 October 2023 for a status update as to the Complaint.

19. Subsequent events

Other than the update on legal proceedings, there are no known subsequent events which have led to adjustments to this set of financial statements.

Other Information Required by Catalist Rule Appendix 7C

A. Review

The condensed consolidated statement of financial position of the Company and its subsidiaries as at 30 June 2023 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and explanatory notes have not been audited or reviewed.

The Company's auditors for the financial year ended 31 December 2022 ("FY2022"), Moore Stephens LLP, had issued a disclaimer of opinion on the Group's financial statements for FY2022 as highlighted from pages 56 to 58 of the Company's Annual Report for FY2022.

Update on efforts to resolve accounting issue arising from the latest audited financial statements for FY2022

Efforts taken to resolve each outstanding audit issue are as follows:

(i) Consolidation of TriReme USA

The Management of the Company is still seeking clarifications from TriReme USA and legal counsels on this matter, pending mutual resolution, has expressly reserved its rights to dispute such purported corporate action of TriReme USA. Accordingly, the Company continues to consolidate TriReme USA as a subsidiary of the Group in the interim consolidated financial statements as at and for the six months ended 30 June 2023.

(ii) Going concern assumption

Please refer to Note 2.1 for the steps taken by management to address the going concern assumption of the Group as at 30 June 2023.

The Board confirms that the impact of the outstanding audit issues on the financial statements have been adequately disclosed.

B. Review of performance of the Group

Condensed interim consolidated statement of profit or loss and other comprehensive income

<u>Six month ended 30 June 2023 ("HY2023") vs six month ended 30 June 2022 ("HY2022")</u>

The Group recorded revenue of S$6.3 million and cost of sales of S$3.5 million for HY2023, which was mainly contributed by the increase in dental businesses from Eastern Dental Centre Pte Ltd ("EDC") and the newly acquired TDH under ADG Group. This resulted in the Group's increase in gross profit by S$934,000 from S$1.9 million in HY2022 to S$2.8 million in HY2023.

In HY2023, the Group's loss before taxation increased by S$1.6 million mainly due to increase in administrative expenses by S$2.4 million in HY2023 comprising (i) S$2.0 million of legal expenses incurred for the InnoRa Arbitration case, and (ii) increase in overall operation expenses for ADG Group due to the acquisition of businesses of three dental clinics via TDH; partially offset by the increase in dental businesses as explained above.

Condensed statements of financial position

Group	As at 30 June 2023 S$'000	As at 31 December 2022 S$'000	Change %
Non-current assets	8,888	7,975	11%
Current assets	4,844	6,934	(30%)
Total assets	13,732	14,909	(8%)
Total equity	(2,269)	(1,628)	39%
Non-current liabilities	(5,769)	(8,156)	(29%)
Current liabilities	(10,232)	(8,381)	22%
Total liabilities	(16,001)	(16,537)	(3%)

Our non-current assets increased by S$913,000 mainly due to:

(i) Increase in goodwill on acquisition of S$1,560,000 from TDH acquisition; partially offset by
(ii) Decrease in right-of-use assets in relation to the office and clinics rental leases of S$515,000.

Our current assets decreased by S$2,090,000 mainly due to:

(i) Decrease in cash and cash equivalents of S$2,736,000 due to reasons presented in the cashflow analysis below; partially offset by
(ii) Increase in trade and other receivables of S$601,000 mainly due to increase in sales and operation from ADG Group, as a result of the acquisition of TDH.

Our non-current liabilities decreased by S$2,387,000 mainly due to:

(i) Decrease in loans and borrowings of S$633,000 due to loans repayment;
(ii) Decrease in amount due to non-controlling interest of S$1,316,000 due to first milestone payment for contingent consideration to Dr Jimmy Gian for the acquisition of ADG in January 2023;
(iii) Decrease in lease liabilities due to Group's rental leases of approximately S$439,000.

Our current liabilities increased by S$1,851,000 mainly due to:

(i) Increase in trade and other payables of S$1,852,000 mainly due to accrual of legal fees payables for InnoRa Arbitration.

The Group has undertaken the steps highlighted in Note 2.1 to address the Group's negative working capital of S$5,388,000 and deficit in shareholders' equity of S$2,269,000 as at 30 June 2023.

Based on the foregoing, the Board confirms that the Group will be able to meet its short-term debt obligations when they fall due based on the implementation of the aforementioned steps and continue to operate as a going concern and confirmed that all material disclosures have been provided for trading of the Company's shares to continue in an orderly manner.

Condensed consolidated statement of cash flows

The Group recorded cash outflows from operating activities of approximately S$524,000 in HY2023 mainly due to:
(i) Operation loss for the period after non-cash adjustments of S$1,664,000;
(ii) Increase in trade receivables and inventories recorded following the acquisition of TDH in February 2023 of approximately S$653,000;
(iii) Tax payment of S$30,000; and
(iv) Offset by increase in overall movement of trade and other payables for approximately S$1,852,000 following the acquisition of TDH in February 2023 and accrual of legal fees payables for InnoRa Arbitration.

Net cash used in investing activities for HY2023 of approximately S$1,601,000 was mainly due to:
(i) purchase of plant and equipment of approximately S$41,000; and
(ii) acquisition of the 100% interests in TDH amounting to approximately S$1,560,000.

Net cash used in financing activities for HY2023 of approximately S$610,000 was mainly due to:
(i) repayment of first milestone payment for contingent consideration to Dr Jimmy Gian for the acquisition of ADG in January 2023 of S$1,383,000;
(ii) repayment of loan borrowings of S$731,000;
(iii) payment of lease liability of S$496,000; and
(iv) Offset by proceeds from the placement exercise in March 2023 of approximately S$2,000,000.

C. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

The 1H2023 result is consistent with the Company's profit guidance announced on 28 July 2023.

D. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Barring any unforeseen circumstances, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next 12 months.

The Company continues to actively explore various strategic options, fund raising opportunities and is continuously acquiring dental business to grow its healthcare business.

E. Dividend information

(1) IF A DECISION REGARDING DIVIDEND HAS BEEN MADE:

(a) Whether an interim (final) ordinary dividend has been declared (recommended); and

No dividends have been declared or recommended for the current reporting period.

(b) (i) Amount per share (cents)

Not applicable.

(ii) Previous corresponding period (cents)

Not applicable.

(c) **Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of the shareholders, this must be stated).**

Not applicable.

(d) **The date the dividend is payable**

Not applicable.

(e) **Books closure date**

Not applicable.

(2) IF NO DIVIDEND HAS BEEN DECLARED/RECOMMENDED, A STATEMENT TO THAT EFECT AND THE REASON(S) FOR THE DECISION

No dividends have been declared or recommended for the current reporting period as the Company wishes to retain the available funds for its working capital.

F. Interested person transactions

There were no interested persons transactions which are S$100,000 or more entered into during the current financial period reported on. The Group does not have a general mandate for recurrent interested persons transactions.

G. Use of proceeds from share subscription

On 28 March 2023, the Company announced the completion of the placement of 571,428,600 new ordinary shares of the Company at the issue price of S$0.0035 per share, which took place on 29 March 2023. The estimated net proceeds is approximately S$1.9 million ("**March 2023 Placement Net Proceeds**")

As at the date of this announcement, the March 2023 Placement Net Proceeds have been utilized as follows:

	Allocation of March 2023 Placement Net Proceeds S$'000	Amount utilised S$'000	Balance S$'000
General working capital purposes (1)	1,920	1,473	447

A breakdown of the March 2023 Placement Net Proceeds utilized for general working capital purposes is as follows:

	S$'000
Payment of salaries and wages	524
Payment to professional fees	462
Repayment of working capital loan	262
Operating costs	225
Total	1,473

The above utilization is in accordance with the intended use of proceeds as stated in the Company's circular dated 11 March 2023. The Company will continue to make periodic announcements via SGXNET on the utilization of the balance of the March 2023 Placement Net Proceeds as and when such proceeds are materially disbursed.

H. Disclosures on incorporation, acquisition and realization of shares pursuant to Catalist Rule 706A

Save as disclosed in Notes 17 above, the Company did not acquire or dispose of any shares resulting in any of the prescribed situations under Rule 706A during HY2023.

During HY2023 and as at the date of this report, the Company had incorporated the following subsidiaries, details of which are set out in the table below:

Name of Entity	Date of Incorporation	Country of Incorporation	% Held by the Group	Paid-Up Capital	Principal Activity
Quantum Healthcare Holdings Sdn Bhd	7 February 2023	Malaysia	60	RM100 (approximately S$30)	Dormant
Quantum Specialist Sdn Bhd	27 February 2023	Malaysia	60	RM100 (approximately S$30)	Dormant

The above incorporations were funded through internal resources and are not expected to have any material impact on the net tangible assets per share or earnings per share of the Group for the financial year ended 31 December 2023.

I. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Catalist Rule 720(1)

The Company has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Catalist Rule 720(1) of the Catalist Listing Manual.

J. Confirmation by the Board pursuant to Rule 705(5) of the Listing Manual

On behalf of the Board of Directors of the Company, we the undersigned, hereby confirm to the best of our knowledge that nothing has come to our attention of the Board of Directors of the Company which may render the unaudited condensed interim financial statements of the Company and the Group for the six-months ended 30 June 2023 to be false or misleading in any material aspect.

By order of the Board of Directors

Thomas Tan Gim Chua
Executive Director and Chief Executive Officer

Sho Kian Hin
Independent Director

Singapore
14 August 2023

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.